FABIOR (nda202428)- (0.1%)

Generic Name	TAZAROTENE	Innovator	MAYNE PHARMA
Dosage	0.1%
ParaIV Filing	No	505(b)2 Filing	No
Last Patent Expiry	2030-Feb-24	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	Fabior Foam is a retinoid indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	None

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.1%	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of FABIOR